Clinical trial NCT06874621: VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Official title: VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Alzheimer&#39;s Disease (AD)
Lead sponsor: Voyager Therapeutics
Sponsor class: INDUSTRY
First posted: 2025-03-13
Enrollment: 52
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 18 months for the highest dose group.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of early AD, defined as:

   1. Meet the NIA-AA core clinical criteria for MCI due to AD or mild AD.
   2. Mini Mental State Examination (MMSE) score between 18 and 30, inclusive, at Screening (Cohort 1 and 2) and score between 22 and 30, inclusive, at Screening (Cohort 3).
   3. Report a history of subjective memory decline with gradual onset and slow progression over at least the last 6 months before Screening; must be corroborated by an informant/caregiver.
   4. CDR Memory Box score ≥0.5 CDR global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD.
2. Evidence of pathology consistent with AD diagnosis:

   1. For Cohort 1 and Cohort 2 only, by documented historical amyloid PET showing imaging agent uptake into the brain conducted within 24 months before screening OR elevated plasma pTau217/np-Tau217 ratio within the Screening Period.
   2. For Cohort 3 only, evidence of pathology consistent with AD diagnosis by both:

      * Evidence of Tau PET imaging agent uptake into the brain by central read AND
      * Evidence of positive brain amyloid pathology as indicated by one of the following:

   <!-- -->

   1. Documented historical amyloid PET showing imaging agent uptake into the brain conducted within 24 months before screening OR
   2. CSF beta amyloid and tau levels consistent with AD diagnosis within the Screening Period.
3. Body mass index (BMI) ≥18 and ≤35 kg/m2 at Screening.
4. Apart from the clinical diagnosis of early AD, participant must be in good health, based on medical history and screening assessments.
5. If participant is receiving an approved symptomatic AD treatment such as but not limited to acetylcholinesterase inhibitor (AChEIs), memantine, rivastigmine, galantamine and tacrine for AD, participant must be on a stable dose for at least 8 weeks prior to Screening.

   1. Treatment-naive participants for AD can be entered into the study.
   2. Unless otherwise stated, participants must have been on stable doses of all other (non-AD-related) permitted concomitant medications for at least 4 weeks prior to Screening.
   3. Participants currently on β amyloid therapies may not be enrolled.
6. Must have an identified reliable informant/caregiver (defined as a person able to support the participant for the duration of the study e.g., spouse, sibling, close friend, who spends at least 10 hours per week with the participant) who assented to:

   1. Accompany the participant to clinic visits.
   2. Provide information to study Investigator/staff about functioning, cognitive abilities and AEs.
   3. Support participants returning for per-protocol follow-up visits and procedures.

Exclusion Criteria:

1. Any medical or neurological/neurodegenerative or psychiatric condition (other than AD) that, in the opinion of the Investigator, may be contributing cause to cognitive impairment or could confound interpretation of drug effect, affect study assessments, or affect participant's ability to participate and complete the study or lead to safety concerns.
2. History of transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening.
3. History of seizures within 10 years prior to screening or history of epileptic syndrome (except for history of febrile seizures in childhood)
4. Lifetime history of a major psychiatric disorder including schizophrenia or bipolar disorder. History of major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime.
5. Presence of a clinically significant uncontrolled medical disorder involving one or more of these major organ systems: cardiovascular (including but not limited to a QTcF of \>470 ms for women and \>450 ms for men and uncontrolled hypertension), respiratory, renal, gastrointestinal, immunologic, hematologic including bleeding disorder, hepatic, or endocrine.
6. Contraindications to lumbar puncture, including but not limited to coagulation or bleeding disorders, unsafe suspension of anticoagulant, infections at the injection site, spinal deformities or previous spinal surgeries that may affect safe LP performance, or conditions associated with increased intracranial pressure.
7. Contraindications to MRI scanning, including but not limited to cardiac pacemaker/defibrillator, ferromagnetic metal implants (devices other than those approved as safe for use in MRI scanners).
8. History of a malignant disease (cancer) except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, in situ prostate cancer with a normal posttreatment prostate-specific antigen within the last five years or other cancers in remission for at least 5 years
9. Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic mAbs (or derivatives of mAbs), systemic immunosuppressants, or plasmapheresis during the study.
10. History of severe allergies, or history of an anaphylactic reaction (nonactive hay fever is acceptable).
11. Participation in a clinical drug trial or device within 30 days (or 5 half-lives, whichever is longer and 3 months for a biologic) of screening, unless the study blind has been broken and the participant was known to be on placebo.
12. Last administration of B-secretase and gamma-secretase inhibitors in a study within 3 months or 5 half-lives (whichever is longer) prior to screening, unless it can be documented that the participant only received placebo.
13. Current use of an approved AD disease modifying or anti-amyloid therapy (including but not limited to any mAb therapies).
14. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for intraoperative or postoperative bleeding.

Primary outcomes:
measure: Characterization of the safety and tolerability of VY7523 in participants with early AD
timeFrame: Cohorts 1 and 2: up to 6 months Cohort 3: up to 18 months
Secondary outcomes:
measure: To characterize the pharmacokinetics (PK) of VY7523 in serum
timeFrame: Cohort 1 & 2: Month 1 - 6 Cohort 3: Month 1-7, 9, 12, 17 and 18
measure: To evaluate the ability of VY7523 to prevent the spread of pathologic tau; Cohort 3 only
timeFrame: Month 6, 12 & 18
measure: To evaluate the immunogenicity of multiple, escalating intravenous (IV) doses of VY7523
timeFrame: Cohort 1 & 2: Month 1, 3, 4, 5 & 6 Cohort 3: Month 1, 2, 6, 9, 12 & 18
measure: To characterize the pharmacokinetics (PK) of VY7523 in cerebrospinal fluid (CSF) concentrations following multiple IV doses
timeFrame: Cohort 1 & 2: Month 6 Cohort 3: Month 12 and 18
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: VYGR Site 840018
state: California
city: Orange
country: United States
facility: VYGR Site 840016
state: California
city: San Francisco
country: United States
facility: VYGR Site 840022
state: California
city: Stamford
country: United States
facility: VYGR Site 840008
state: Connecticut
city: Delray Beach
country: United States
facility: VYGR Site 840005
state: Florida
city: Fort Myers
country: United States
facility: VYGR Site 840021
state: Florida
city: Lady Lake
country: United States
facility: VYGR Site 840010
state: Florida
city: Miami
country: United States
facility: VYGR Site 840015
state: Florida
city: Miami
country: United States
facility: VYGR Site 840014
state: Florida
city: Miami
country: United States
facility: VYGR Site 840024
state: Florida
city: Orlando
country: United States
facility: VYGR Site 840006
state: Florida
city: Stuart
country: United States
facility: VYGR Site 840003
state: Florida
city: The Villages
country: United States
facility: VYGR Site 840004
state: Florida
city: Wellington
country: United States
facility: VYGR Site 840002
state: Florida
city: Winter Park
country: United States
facility: VYGR Site 840020
state: Florida
city: Columbus
country: United States
facility: VYGR Site 840017
state: Georgia
city: Decatur
country: United States
facility: VYGR Site 840007
state: Georgia
city: Toms River
country: United States
facility: VYGR Site 840012
state: New Jersey
city: Matthews
country: United States
facility: VYGR Site 840009
state: North Carolina
city: Allentown
country: United States
facility: VYGR Site 840023
state: Pennsylvania
city: Plymouth Meeting
country: United States
facility: VYGR Site 840011
state: Pennsylvania
city: Ottawa
country: Canada
facility: VYGR Site 124002
state: Ontario
city: Toronto
country: Canada
facility: VYGR Site 124001
state: Ontario
city: Montreal
country: Canada
facility: VYGR Site 124003
state: Quebec
city: Montreal
country: Canada
facility: VYGR Site 124004
state: Quebec
Study officials:
affiliation: Voyager Therapuetics, Inc.
name: Chief Medical Officer
role: STUDY_DIRECTOR
References: